Literature DB >> 31019039

Intra- and Interobserver Agreement of SUV SPECT Quantitative SPECT/CT Processing Software, Applied in Clinical Settings for Patients with Solid Renal Tumors.

Antonios Tzortzakakis1,2, Maria Holstensson3, Eva Hagel4, Mattias Karlsson3, Rimma Axelsson5,3.   

Abstract

Quantification tools for SPECT/CT are a field of ongoing research among hybrid imaging techniques. A recent multicenter study evaluating SUV SPECT software on phantoms showed that quantitative SPECT/CT is reproducible in Hybrid Viewer software. The aim of our study was to evaluate the intra- and interobserver agreement of quantitative SUV SPECT measurements in clinical settings for patients with solid renal tumors.
Methods: The evaluation was part of a study that examined the role of 99mTc-sestamibi SPECT/CT in the characterization of solid kidney tumors and the differentiation of renal oncocytomas from renal cell carcinomas. Quantitative evaluation of SUV measurements was performed in Hybrid Viewer PDR, version 2.5. Forty-eight renal lesions were identified and examined twice by 2 independent readers. The agreement of the SUV measurements, concerning renal tumors and adjacent renal parenchyma, was evaluated using the intraclass correlation coefficient (ICC).
Results: ICC for SUVmax measurements by the same reader was 97%-99% for solid renal tumors and 92%-98% for ipsilateral healthy renal parenchyma. ICC for SUVmax measurements between readers was 87%-89% for solid renal tumors and 72%-73% for ipsilateral healthy renal parenchyma. Estimated ICC for SUVmean measurements of solid renal tumors was 95%-98% for the same reader and 86%-89% between readers. Similar results were found for SUVpeak measurements.
Conclusion: The high ICCs indicate a strong agreement among SUV measurements for patients with solid renal lesions undergoing 99mTc-sestamibi SPECT/CT, not only for measurements by the same reader but also for measurements between 2 different readers.
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  99mTc-sestamibi SPECT/CT; SPECT/CT; SUV SPECT; SUV SPECT/CT; quantitative SPECT/CT

Year:  2019        PMID: 31019039     DOI: 10.2967/jnmt.118.223297

Source DB:  PubMed          Journal:  J Nucl Med Technol        ISSN: 0091-4916


  4 in total

Review 1.  A review of 99mTc-sestamibi SPECT/CT for renal oncocytomas: A modified diagnostic algorithm.

Authors:  Mitchell P Wilson; Prayash Katlariwala; Jonathan Abele; Gavin Low
Journal:  Intractable Rare Dis Res       Date:  2022-05

2.  Usefulness of quantitative 99mTc-pyrophosphate SPECT/CT for predicting the prognosis of patients with wild-type transthyretin cardiac amyloidosis.

Authors:  Kouji Ogasawara; Shinya Shiraishi; Noriko Tsuda; Fumi Sakamoto; Seitarou Oda; Seiji Takashio; Kenichi Tsujita; Toshinori Hirai
Journal:  Jpn J Radiol       Date:  2022-01-01       Impact factor: 2.374

3.  Quantitative myocardial perfusion SPECT/CT for the assessment of myocardial tracer uptake in patients with three-vessel coronary artery disease: Initial experiences and results.

Authors:  Sebastian Lehner; Isabel Nowak; Mathias Zacherl; Julia Brosch-Lenz; Maximilian Fischer; Harun Ilhan; Johannes Rübenthaler; Astrid Gosewisch; Peter Bartenstein; Andrei Todica
Journal:  J Nucl Cardiol       Date:  2021-08-02       Impact factor: 3.872

4.  In Situ Metabolomics Expands the Spectrum of Renal Tumours Positive on 99mTc-sestamibi Single Photon Emission Computed Tomography/Computed Tomography Examination.

Authors:  Thomas Papathomas; Antonios Tzortzakakis; Na Sun; Franziska Erlmeier; Annette Feuchtinger; Kiril Trpkov; Alina Bazarova; Alexandros Arvanitis; Wanzhong Wang; Bela Bozoky; Georgia Kokaraki; Rimma Axelsson; Axel Walch
Journal:  Eur Urol Open Sci       Date:  2020-11-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.